Revisiting the possibility of serious adverse events from the whole cell pertussis vaccine: Were metabolically vulnerable children at risk?

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 150-154

  Wilson, Kumanan ^a,b   Potter, Beth ^b   Manuel, Douglas ^a   Keelan, Jennifer ^c   Chakraborty, Pranesh ^b,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PERTUSSIS VACCINE;

ANOREXIA; ARTICLE; BRAIN DISEASE; CHILD; CLINICAL TRIAL; DRUG FEVER; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FATTY ACID OXIDATION; FEVER; HUMAN; HYPOGLYCEMIA; IMMUNITY; INBORN ERROR OF METABOLISM; INFLAMMATION; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; PERTUSSIS; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SUDDEN INFANT DEATH SYNDROME; UNITED STATES; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANOREXIA; FATTY ACIDS; FEVER; HUMANS; HYPOGLYCEMIA; INFANT; METABOLISM, INBORN ERRORS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PERTUSSIS VACCINE; SUDDEN INFANT DEATH; VACCINATION; WHOOPING COUGH;

EID: 70450255137     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.07.014     Document Type: Article

References (39)

1. Baker J.P. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine 21 25-26 (2003) 4003-4010
2. Walker A.M., Jick H., Perera D.R., Thompson R.S., and Knauss T.A. Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 77 8 (1987) 945-951
3. Cherry J.D. 'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA 263 12 (1990) 1679-1680
4. Ray P., Hayward J., Michelson D., et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Infect Dis J 25 9 (2006) 768-773
5. Hinman A.R. Addressing the vaccine financing conundrum. Health Aff (Millwood) 24 3 (2005) 701-704
6. Evans G. Update on vaccine liability in the United States: presentation at the national vaccine program office workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002. Clin Infect Dis 42 Suppl. 3 (2006) S130-S137
7. Ridgway D. No-fault vaccine insurance: lessons from the national vaccine injury compensation program. J Health Polit Policy Law 24 1 (1999) 59-90
8. Fritzell B. Detection of adverse events: what are the current sensitivity limits during clinical development?. Vaccine 20 Suppl. 1 (2001) S47-S48
9. Verweij M., and Dawson A. Ethical principles for collective immunisation programmes. Vaccine 22 23-24 (2004) 3122-3126
10. Institute of Medicine. Immunization safety review. Vaccines and autism (2004), The National Academies Press, Washington, DC
11. Wilson K., Mills E., Ross C., McGowan J., and Jadad A. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 157 7 (2003) 628-634
12. Parikh R. What the Poling autism case means? Salon.com; 2008.
13. Brady M.T. Immunization recommendations for children with metabolic disorders: more data would help. Pediatrics 118 2 (2006) 810-813
14. Offit P.A. Vaccines and autism revisited - the Hannah Poling case. N Engl J Med 358 20 (2008) 2089-2091
15. Grosse S.D., Khoury M.J., Greene C.L., Crider K.S., and Pollitt R.J. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 8 4 (2006) 205-212
16. Schuler A.M., and Wood P.A. Mouse models for disorders of mitochondrial fatty acid beta-oxidation. ILAR J 43 2 (2002) 57-65
17. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Valle D, Sly WS, editors. The online metabolic and molecular bases of inherited disease. McGraw-Hill; 2001. Available from: http://genetics.accessmedicine.com/mmbid/public/.
18. Harrington P., Woodman C., and Shannon W. Low immunisation uptake: is the process the problem?. J Epidemiol Commun Health 54 (2000) 394-400
19. Clarke J.T.R. A clinical guide to inherited metabolic diseases (2006), Cambridge University Press, New York
20. Waddell L., Wiley V., Carpenter K., et al. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab 87 1 (2006) 32-39
21. Wilcken B., Haas M., Joy P., et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369 9555 (2007) 37-42
22. Wilson D., Bressani R., and Scrimshaw N.S. Infection and nutritional status. I. The effect of chicken pox on nitrogen metabolism in children. Am J Clin Nutr 9 (1961) 154-158
23. Centres for disease control and prevention. Possible side-effects from vaccines. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm#dtap.
24. Scrimshaw N.S. Rhoades lecture. Effect of infection on nutrient requirements. JPEN J Parenter Enter Nutr 15 6 (1991) 589-600
25. Wilson J.M., and Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65 4 (1968) 281-393
26. Kingsley J.D., Varman M., Chatterjee A., Kingsley R.A., and Roth K.S. Immunizations for patients with metabolic disorders. Pediatrics 118 2 (2006) e460-e470
27. Ziadeh R., Hoffman E.P., Finegold D.N., et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 37 5 (1995) 675-678
28. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No.RR-7):1-25.
29. An Advisory Committee Statement (ACS). National advisory committee on immunization (NACI). Statement on pertussis vaccine. Can Commun Dis Rep 23 ACS-3 (1997)
30. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 6 (1996) 349-355
31. Decker M.D., Edwards K.M., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96 3 Pt 2 (1995) 557-566
32. In: Stratton K., Almario D.A., Wizemann T.M., and McCormick M.C. (Eds). Immunization safety review: vaccinations and sudden unexpected death in infancy (2003), The National Academies Press, Washington, DC
33. Fine P.E., and Chen R.T. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136 2 (1992) 121-135
34. Farrington P., Pugh S., Colville A., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345 8949 (1995) 567-569
35. Farrington C.P., Miller E., and Taylor B. MMR and autism: further evidence against a causal association. Vaccine 19 27 (2001) 3632-3635
36. Farrington C.P., Nash J., and Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 143 11 (1996) 1165-1173
37. Taylor B., Miller E., Farrington C.P., et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 353 9169 (1999) 2026-2029
38. Miller E., Andrews N., Grant A., Stowe J., and Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Arch Dis Child 90 3 (2005) 292-296
39. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., and Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351 25 (2004) 2611-2618